Author:
Arantes Flávia B. B.,Menezes Fernando R.,Franci Andre,Barbosa Carlos J. D. G.,Dalçoquio Talia F.,Nakashima Carlos A. K.,Baracioli Luciano M.,Furtado Remo H. M.,Nomelini Quintiliano S. S.,Ramires José A. F.,Kalil Filho Roberto,Nicolau José C.
Funder
Sao Paulo Research Foundation
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference30 articles.
1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
2. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.
3. Fiessinger JN, Huisman MV, Davidson B, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681–9.
4. Xiao Z, Theróux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–6.
5. Ferguson J, Califf R, Atman E, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA. 2004;292:45–54.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献